Yu Qing, Liu Shan-Ling, Wang He, Shi Gang, Yang Pei, Chen Xin-Lian
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu,China E-mail :
Asian Pac J Cancer Prev. 2014 Jan;14(11):6569-72. doi: 10.7314/apjcp.2013.14.11.6569.
In cervical cancer, one of the most common malignant tumors in women worldwide, miR-126 has been reported to exhibit decreased expression. However, its role in cervical cancer cell proliferation and drug sensitivity has remained relatively unexplored. Here, we compared the expression of miR-126 in cervical cancer tissues (n = 20) with that in normal cervical tissue (n = 20) using quantitative RT-PCR. The viability of Siha cervical cancer cells was further measured by MTT assay after transfection with miR-126 mimic (Siha-miR-126 mimic) or microRNA mimic negative control (Siha-miR mimic NC) and after treatment with various concentrations of bleomycin (BLM). IC50s were calculated, and the survival rates (SRs) of Siha cells were calculated. miR-126 expression in cervical cancer tissue was significantly decreased compared with that in normal cervical tissue (P < 0.01). The relative SRs of Siha-miR-126 mimic cells were also significantly decreased compared with those of Siha-miR mimic NC cells at 24-96 h after transfection. The IC50 of BLM in Siha-miR-126 mimic cells (50.3 ± 2.02 μg/mL) was decreased compared with that in Siha-miR mimic NC cells (70.5 ± 4.33 μg/mL) at 48 h after transfection (P < 0.05). Finally, the SRs of Siha-miR-126 mimic cells were significantly lower than those of Siha- miR mimic NC cells after cultured in medium containing 40 μg/mL BLM for 24-96 h (P < 0.05). These results suggest that miR-126 is expressed at low levels in cervical cancer. Upregulation of miR-126 inhibited cervical cancer cell proliferation and enhanced the sensitivity to BLM. Thus, miR-126 may represent a novel approach to cervical cancer treatment.
在子宫颈癌（全球女性中最常见的恶性肿瘤之一）中，据报道miR - 126表达降低。然而，其在子宫颈癌细胞增殖和药物敏感性方面的作用仍相对未被探索。在此，我们使用定量逆转录聚合酶链反应（qRT - PCR）比较了20例子宫颈癌组织和20例正常子宫颈组织中miR - 126的表达。在用miR - 126模拟物（Siha - miR - 126模拟物）或微小RNA模拟物阴性对照（Siha - miR模拟物NC）转染后，以及用不同浓度的博来霉素（BLM）处理后，通过MTT法进一步检测Siha子宫颈癌细胞的活力。计算半数抑制浓度（IC50），并计算Siha细胞的存活率（SR）。与正常子宫颈组织相比，子宫颈癌组织中miR - 126的表达显著降低（P < 0.01）。转染后24 - 96小时，Siha - miR - 126模拟物细胞的相对存活率也与Siha - miR模拟物NC细胞相比显著降低。转染后48小时，Siha - miR - 126模拟物细胞中BLM的IC50（50.3±2.02μg/mL）与Siha - miR模拟物NC细胞（70.5±4.33μg/mL）相比降低（P < 0.05）。最后，在含有40μg/mL BLM的培养基中培养24 - 96小时后，Siha - miR - 126模拟物细胞的存活率显著低于Siha - miR模拟物NC细胞（P < 0.05）。这些结果表明，miR - 126在子宫颈癌中低表达。miR - 126的上调抑制子宫颈癌细胞增殖并增强对BLM的敏感性。因此，miR - 126可能代表一种子宫颈癌治疗的新方法。
